Kyowa Hakko Kirin Submits Listing Application of Crysvita for FGF-23-related Hypophosphatemic Rickets and Osteomalacia

Kyowa Hakko Kirin announced submission of Crysvita (burosumab, KRN23) to the Japanese Ministry of Health, Labor and Welfare (MHLW) for the treatment of FGF-23-related hypophosphatemic rickets and osteomalacia. The active ingredient ofRead More…